The myocardial protection of htk cardioplegic solution on the long-term ischemic period in pediatric heart surgery

ASAIO Journal

Volumn 54, Issue 5, 2008, Pages 470-473

  Liu, Jinping ^a   Feng, Zhengyi ^a   Zhao, Ju ^a   Li, Bo ^a   Long, Cun ^a,b  

^a FUWAI HOSPITAL   (China)

^b NONE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC SURGERY; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CLINICAL EXPERIENCE; KETOGLUTARATE; LONG TERM; MYOCARDIAL PROTECTION; OPEN-HEART SURGERY; PEDIATRIC HEART SURGERIES; POST-OPERATIVE DAYS; REPERFUSION;

AMINO ACIDS;

SURGERY;

ADRENALIN; CREATINE KINASE; DOBUTAMINE; DOPAMINE; HEPARIN; HTK SOLUTION; PROTAMINE; ST THOMAS HOSPITAL SOLUTION; 2 OXOGLUTARIC ACID; CARDIOPLEGIC AGENT; HISTIDINE; TRYPTOPHAN;

AORTA CLAMPING; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CHILD; CONFERENCE PAPER; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEFIBRILLATION; FEMALE; HEART BEAT; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RATE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OPEN HEART SURGERY; PEDIATRIC SURGERY; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SURGICAL MORTALITY; TREATMENT DURATION; TREATMENT RESPONSE; ARTICLE; BLOOD; CASE CONTROL STUDY; CHEMISTRY; COHORT ANALYSIS; HEART SURGERY; METHODOLOGY; PERFUSION; REPERFUSION INJURY;

CARDIAC SURGICAL PROCEDURES; CARDIOPLEGIC SOLUTIONS; CARDIOPULMONARY BYPASS; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; COHORT STUDIES; CREATINE KINASE; FEMALE; HISTIDINE; HUMANS; INFANT; KETOGLUTARIC ACIDS; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PERFUSION; RETROSPECTIVE STUDIES; TRYPTOPHAN;

EID: 55949083114     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e318188b86c     Document Type: Conference Paper

References (19)

1. Hearse DJ, Bolli R: Reperfusion induced injury: Manifestations, mechanism and clinical relevance. Cardiovasc Res 26: 101-105, 1992.
2. Careaga G, Argüero R, Chávez-Negrete A, et al: Control of myocardial reperfusion injury with hypertonic-hyperosmotic solution in isolated rabbit heart. Eur Surg Res 27: 269-76, 1995.
3. García-Dorado D, Oliveras J: Myocardial oedema: A preventable cause of reperfusion injury? Cardiovasc Res 27: 1555-1557, 1993.
4. Kober IM, Obermayer RP, Brüll T, et al: Comparison of the solutions of Bretschneider, St. Thomas' Hospital and the National Institutes of Health for cardioplegic protection during moderate hypothermic arrest. Eur Surg Res 30: 243-247, 1998.
5. Hendry PJ, Labow RS, Keon WJ: A comparison of intracellular solutions for donor heart preservation. J Thorac Cardiovasc Surg 105: 667-670, 1993.
6. Sakata J, Morishita K, Ito T, et al: Comparison of clinical outcome between histidine-tryptophan-ketoglutarate solution and cold blood cardioplegic solution in mitral valve replacement. J Card Surg 13: 43-49, 1998.
7. Schaper J, Scheld HH, Schmidt U, Hehrlein F: Ultrastructural study comparing the efficacy of five different methods of intraoperative myocardial protection in the human heart. J Thorac Cardiovasc Surg 92: 47-55, 1986.
8. Heinemeyer D, Belles G, Stapenhorst K: Intracellular pH measurement during cardiac arrest in ventricular myocardium by Bretschneider's cardioplegic solution HTK and St. Thomas Hospital solution with and without procaine. Thorac Cardiovasc Surg 35: 48-52, 1987.
9. Careaga G, Salazar D, Téllez S, et al: Clinical impact of histidineketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients. Arch Med Res 32: 296-299, 2001.
10. Keeling IM, Obermayr RP, Schneider B, Spieckermann PG: Postischemic cardiac function recovery in the isolated rat heart: Effects of adenosine deaminase and nucleoside transport inhibition. Langenbecks Arch Surg 385: 531-537, 2000.
11. Guifen Li, Shigang Wang, Qiang Hu, et al. The observation of Bretschneider's cardioplegia solution on infants' immature myocardial protection. Chin J ECC 4: 9-11, 2006.
12. Murashita T, Yasuda K: Comparison of the protective properties of St. Thomas,' Tyers,' and Bretschneider's cardioplegic solution in the neonatal rabbit heart. Nippon Kyobu Geka Gakkai Zasshi 44: 2019-2026, 1996.
13. Camilleri L, Moins N, Mouchonière M, et al: Cultured neonatal rat cardiomyocytes and 99mTc-sestamibi to assess the direct effects of cardioplegia. Cardiovasc Surg 6: 614-621, 1998.
14. Podesser B, Wollenek G, Windischbauer A, et al: Myocardial protection with Bretschneider cardioplegic solution-an evalution of full oxygenation. Eur Surg Res 26: 133-140, 1994.
15. Grice M, Konishi T, Apstein CS: Resistance of neonatal myocardium to injury during normothermic and hypothermic ischemic arrest and reperfusion. Circulation 76: 150-155, 1987.
16. Kresh JY, Nastala C, Bianchi PC, et al: The relative buffering power of cardioplegic solutions. J Thorac Cardiovasc Surg 93: 309-311, 1987.
17. del Nido PJ, Wilson GJ, Mickle DA, et al: The role of cardioplegic solution buffering in myocardial protection. A biochemical and histopathological assessment. J Thorac Cardiovasc Surg 89: 689-699, 1985.
18. Hachida M, Nonovama M, Bonkohara Y, et al: Clinical assessment of prolonged myocardial preservation for patients with a severely dilated heart. Ann Thorac Surg 64: 59-63, 1997.
19. Takeuchi K, Akimoto H, Maida K, et al: Myocardial protection of the pressure overload hypertrophied heart in human cardiac surgery by acceleration of anaerobic glycolysis. J Cardiovasc Surg 43: 37-41, 2002.